Intratumoral Cancer Therapies

Intratumoral Cancer Therapies

The intratumoral cancer therapies market is expected to register a CAGR of approx. 9.9% over the period of 2023-2030. Intratumoral cancer therapies are a type of cancer treatment that involves delivering therapeutic agents directly into the tumour site. Unlike systemic treatments, which circulate throughout the entire body, intratumoral therapies target cancer cells within the tumour while minimizing exposure to healthy tissues. Growing advancements in immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses, are driving interest in intratumoral applications. These therapies stimulate the body's immune response to target and destroy cancer cells directly within the tumour site. For instance, in February 2021, the FDA approved Merck's Keytruda (pembrolizumab) for the treatment of high-risk, non-muscle invasive bladder cancer unresponsive to BCG therapy. This approval highlights the potential of immunotherapies in intratumoral applications. Furthermore, the trend toward personalized medicine is driving the development of intratumoral therapies tailored to individual patients' genetic profiles and tumour characteristics. This approach improves treatment effectiveness and reduces side effects.

• Based on the technology, the market has been categorized into monoclonal antibodies, cell and gene therapies, cytokines, and others. Among them, the monoclonal antibodies segment is expected to grow at a higher CAGR in the market due to their potential to target specific cancer cells, trigger immune responses, and minimize off-target effects. Monoclonal antibodies have been widely used in systemic cancer treatments, and their application in intratumoral therapies is gaining traction due to their precision and effectiveness. For instance, GSK's antibody-drug conjugate, Blenrep (belantamab mafodotin-blmf), was granted FDA approval for the treatment of relapsed or refractory multiple myeloma.
• Based on the application, the market has been categorized into lung cancer, breast, melanoma, prostate cancer, and others. Among them, the lung cancer segment is expected to grow at a higher CAGR in the market due to the high incidence of lung cancer and the increasing adoption of innovative therapies to address this challenging disease. Moreover, standard treatments for lung cancer, such as surgery, chemotherapy, and radiation, can have limitations and significant side effects. Intratumoral therapies aim to address these challenges by targeting the tumor cells while minimizing damage to healthy tissues. For instance, in 2021, Varian Medical Systems, are developing innovative techniques for localized treatment of NSCLC, including intratumoral therapies named Elekta. These techniques aim to target tumours within the lung while minimizing damage to healthy lung tissue.
• Based on the end-user, the market has been categorized into hospitals, radiation therapy center, and cancer research institutes. Among them, the hospital category is to witness higher adoption of intratumoral cancer therapies during the forecast period. The rising incidence of cancer and the growing awareness of cancer among the general population has led to an increased number of patients seeking medical attention and technology at hospitals. In addition, hospitals offer a multidisciplinary approach to bringing together various specialists such as endocrinologists, surgical oncologists, medical oncologists, radiologists, and pathologists to provide comprehensive and personalized care to cancer patients. Moreover, Hospitals often have surgical teams experienced in performing complex thyroid surgeries, including total thyroidectomy and lymph node dissection, which are essential in the management of cancer.
• For a better understanding of the market adoption of intratumoral cancer therapies, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. The North America intratumoral cancer therapies market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of intratumoral cancer therapies among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.
• Some of the major players operating AstraZeneca, Amgen Inc., Eli Lilly and Company, AbbVie Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc, Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co among others. Several M&A’s along with partnerships have been undertaken.